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IMMUNOREGULATORY cytokines produced by the TH1 subset
andbyCD8 T lymphocytes appear to brake naturally and
sometimes arrest the progress of HIV infection in the
early phase. It appears reasonable to assume that a mild
and equilibrated stimulation of the immune system may
prevent or delaythe fatal transition towards the prevalent
production ofTH2-type cytokines. The problem is how to
stimulate the immune system in a physiological fashion.
In the last 7 yearswe have clarified the main mechanisms
of action of an unorthodox immunotherapeutic method
first used 40 years ago. Optimized autohaemotherapy
after a briefexposure ofblood to ozone may today afford
the trick of reprogramming the immune system to keep
HIV at bay. The autohaemotherapeutic procedure is
simple, safe, inexpensive and most likely is more
effective than conventional approaches.
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Introduction
Projections of the magnitude of human
immunodeficiency virus (HIV) infection by the end
of the century range between 20 and 40 million
worldwide but valid vaccination is not yet in sight.
A number of therapeutic approaches based on the
use of reverse transcriptase inhibitors, antisense
oligonucleotides, proteinase inhibitors, and gene
therapy are under active investigation but their
final efficacy remains uncertain owing to the hetero-
geneity of the virus and the rapid emergence
of mutants.
On the other hand, great progress has been made
in the understanding of HIV pathogenesis1-4 and
recently some immunological characteristics of either
long-term non-progressors or/and high-risk
seronegative individuals have suggested that cell-
mediated anti-HIV response, soon after infection,
may be crucial for controlling the progression of the
disease. 4,5 More specifically, it appears that CD8
lymphocytes present in long-term survivors may re-
lease an as yet unidentified cytokine (momentarily
denominated cell antiviral factor or CAF), heat and
acid-stable, capable of blocking HIV transcription.6,7
There is now some consensus that besides the
activity of the hypothetical CAF, a prevalent and
persistent production of type-1 cytokines (supported
by CD4 TH1 cells) such as interleukin (IL)-2, 12,
granulocyte-macrophage colony stimulating factor
*Dedicated to the memory of Giovanni Battista Rossi
(deceased 20 February, 1994), who was the main force for
the study of HIV infection in Italy.
(GM-CSF) and interferon (IFN)7-13 over the produc-
tion of humoral immunity (supported by CD4 TH2
cells) inducing type-2 cytokines as IL-4, 5, 6, 10 and
1314-19 may prevent or delay the progression of HIV
infection. It is noteworthy that either THl-type or
TH2-type cytokines can in vitro, either prevent or
markedly increase, respectively, apoptosis of CD4
cells thus, at least in part explaining the inexorable
fall of CD4 cells in blood, that has become a hall-
mark of acquired immunodeficiency (AIDS).x-3,’
Moreover, for a long time it has been known that the
acid-labile IFN0t, present in the sera ofAIDS patients,
correlates with disease progression and is an in-
auspicious prognostic marker. ’,’" Indeed the exces-
sive production of IFNz may be detrimental because,
by enhancing MHC restricted and unspecific killing
of virus infected cells, it accelerates the exhaustion
of the lymphocyte pool.
At the present time, therefore, it can be concluded
that in the late phase of HIV infection, an excessive
production of certain cytokines such as IL-4, 6, 10, 13,
IFNcz, tumour necrosis factor-0t (TNF),2-25 and trans-
forming growth factor- (TGF-[3)’6,7 favours the
progressive failure of the immune system. If this as-
sumption is correct, one should devise a therapeutic
strategy aiming not only at correcting the immune
dysregulation, but rather at potentiating the early
attempt of the host’s immune system to block or
eradicate the infection.
Previous approaches based either on the
exogenous administration of biological response
modifiers or type-1 cytokines9,1,s- have been mod-
estly successful or palliative and this is not surprising
because pharmacological administration of cyto-
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kines, as has been observed in cancer therapy, tends
to dysregulate the cytokine network and to yield
considerable toxicity. 32,33
The alternative possibility put forward in this paper
is to stimulate the host’s early response to the virus,
and try to potentiate the immune response that is
apparently functioning well in long-term non-
progressors. Although these subjects may be infected
with a less cytopathic HIV strain than short-term
survivors, it is possible that the latter, who are unfor-
tunately the majority, have either an intrinsic defect
or/and their immune system deranges more rapidly
and becomes incapable of mounting an effective
anti-HIV response.
This particular immune deficiency may be cor-
rected by treating HIV asymptomatic individuals
with a fairly normal T lymphocyte CD4 level with a
therapeutic procedure that, although unorthodox,
has already been extensively tested in chronic viral
diseases and is very simple to execute, safe, inexpen-
sive and free of side effects. 34-39 The scope of this
paper is to evaluate pros and cons of this approach
that, by using the available markers for disease stag-
ing and therapy monitoring can be put to the test in
clinical trials immediately. As autohaemotherapy has
amply proved37-4 to be safe and atoxic, we can
undertake a phase II study directly.
Which are the biological effects elicited
by autohaemotherapy?
While ozone is the trigger, several blood compo-
nents such as erythrocytes, lymphocytes, monocytes,
polymorphonuclear leukocytes, platelets, and
plasma components act as substrates4 and are re-
sponsible for setting in motion a number of biologi-
cal effects that, directly or indirectly, are responsible
for the clinical improvement observed after the
autohaemotherapeutic treatment in chronic viral dis-
eases. (Table 1.)
Ozone is a very reactive gas and yet, when present
in dry air at 22C, it has a half-life of about 40 min. 38
However, when it comes into contact with biological
fluids, such as plasma or the lung lining fluid, it reacts
immediately, particularly if the pH is below 7.4.
Decomposition of ozone generates a cascade of
chemical compounds such as ozonides, aldehydes,
hydroxyhydroperoxides, hydrogen peroxide and
lipid hydroperoxides
41 that have longer lifetimes than
ozone and if unquenched, can penetrate into the
cells.
Ozone has very limited specificity but preferred
substrates, in decreasing order, are mono- and poly-
unsaturated fatty acids, cholesterol, free and protein
bound cysteine, methionine, tyrosine, tryptophane,
histidine and free and bound carbohydrates present
in glycoproteins. All these compounds, present in
cellular membranes,4’-44 in plasma and in viruses, can
Table 1. Relationship between blood cells and targets sensitive to
effector molecules when ozone is the inducer
Blood Effector Targets
components molecules
Erythrocytes
Monocytes
Lymphocytes
Granulocytes
Platelets
Plasma
Cytokines T and B
lymphocytes
Growth hormone Monocytes
Growth inhibitors
Metabolites
Eicosanoids
Macrophages
Granulocytes
Cytotoxic
lymphocytes
Natural killer
cells
Hepatocytes,
Endothelial,
haematopoietic,
virus infected,
and neoplastic
cells
react with ozone and its derivatives with more or less
severe alterations. However, reactions are somewhat
hindered or turned off by the presence either in the
plasma or in the cellular cytoplasm by an array of
antioxidant compounds,45 such as ascorbic acid,
uric acid glucose, a-tocopherol, -carotene, lyco-
pene, reduced glutathione and albumin. Therefore,
it should be made clear that the oxidant properties
of ozone on cellular and viral substrates depend
upon ozone concentration and length of exposure,
pH, temperature and last but not least, by the variable
presence of ’scavengers’ or electron donor com-
pounds.45
The action of ozone derivatives on blood cells is
mainly, if not exclusively, limited to their surface and,
as reviewed extensively in previous articles,4,46 re-
suits in an activation of either their metabolism or in
their induction with consequent release of a number
of cytokine (IFNs, ILs, haemopoietins),4>51 growth
regulatory factors, and aproteinaceous compounds
such as adenosine tri-phosphate (ATP) and possibly
eicosanoids (Table 1), as if the sudden and brief
exposure of blood to 0,./0 switches on a great
number of cellular mechanisms. Furthermore the
unusual feeling of well-being noticed by most of the
patients during autohaemotherapy suggests the
possibility that biological effects are not limited to
the stimulation of blood cells but, owing to a
sudden homeostatic change, there occurs a
neuroendocrinological modification, the relevance
of which cannot be fully understood until we can
investigate the variation of several hormonal param-
eters before and after the therapy. However, it must
be said that the complexity of biological effects
resulting from the interaction between 0,/0 on one
side and the biological system on the other, are
neither easily predictable, nor constantly reproduc-
316 Mediators of Inflammation Vol 3. 1994ible as we are dealing with patients differing from
genetic make-up, age, sex, hormonal, metabolic sta-
tus, type of diet, pathology and most importantly for
a variable amount of antioxidant compounds in their
plasma.49-51
A remark is needed in regard to the virucidal effect
of ozone. There is no doubt that ozone is a potent
virucidal agent52-54 that, by preferentially promoting
lipid peroxidation, can inactivate more effectively
lipid-enveloped viruses i.e. HIV than those with
minimal lipid content. However, it is well known that
in viral diseases most of the virus is located
intracellularly while the free virus, except during the
viraemic phase, is scarcely present in the circulation.
During haemotherapy, practically only virus-infected
cells present in blood can be directly exposed to O2/
03, while most of the virus replicates in far less
accessible organs such as liver, spleen, bone marrow,
lymph nodes and central nervous system. Although
the postulations55 that viral infected cells may have a
decreased content of protective enzymes against
oxidation still holds true, thus rendering these cells
more sensitive to the oxidative effects of ozone
derivatives, it remains difficult to envisage that
ozonization of only a small percentage of the blood
mass would be able to translate such a significant
oxidative effect on the whole organism enough to
reduce the virus burden. While it is true that lipid
hydroperoxides have a fairly long half-life, hence
theoretically they could reach any body fluid, within
a few hours they are inactivated by ubiquitous chain-
breaking compounds such as ot-tocopherol.45 (Bocci
et al., manuscript in preparation).
Moreover, even though viral infected cells present
in blood are more susceptible to oxidation, they most
likely survive because one of the requisites of the
ozone treatment is to avoid a serious intracellular
damage. Then how does ozone act?
As purported before,46 our working hypothesis is
that ozone acts mainly by inducing blood
mononuclear cells to produce immunoregulatory
cytokines, particularly those produced by
lymphocytes with TH1 phenotype. After incubation
of ozonized blood we have shown47-51 the release of
small amounts of practically all cytokines so far
tested, particularly GM-CSF, IL-2, IL-8, IFN,, TNF
and IFN. After reinfusion of ozone-treated blood,
mononuclear cells are supposed to home in various
lymphoid (spleen, lymph nodes, thymus, Peyer’s
patches) and non-lymphoid (lungs, liver) organs thus
priming and activating other immune cells (Fig. 1)
The prolonged repetition of autohaemotherapy
favours a progressively amplified activation of the
immune system via numerous pathways such as
activation of either major histocompatibility com-
plex-restricted cytolysis, or nonspecific killing via
activation of natural-killer cells, macrophages and
neutrophils, that ultimately represents the most effi-
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cient system of destruction of viral infected cells.
Although it may be a minor mechanism, the possibil-
ity cannot be excluded that the small amounts of free
virus inactivated in the plasma during ozonization
may act either as an endogenous immunogen or/and
an activator of cell-mediated immunity. The possibil-
ity that ozone and derivatives may also inactivate
either the viral gp 120, or gp 41, or the cellular
receptor(s) (CD4 and CD26 for HIV) remains to be
demonstrated as ozone acts preferentially on
phospholipids. The activation of metabolism and
possibly psychosomatic factors may play ancillary
roles.
Some advice regarding the most
suitable administration of ozone and
of the optimized procedure
This topic is important because ozone has in my
opinion, a low therapeutic index and we must strive
to achieve an effective immunostimulation with the
least cellular toxicity. It suffices here to say that
during the last 4 years we have extensively evaluated
the toxic effects by measuring the level of ozone
induced haemolysis (below 3.5%),49-51 possible for-
mation of metahaemoglobin (always absent), mor-
phologic damage (absent below 80 l.tg/ml of ozone)
as evaluated by electron microscopy, plasma levels
of lipid hydroperoxides (increasing 3-fold after
ozonization with 90 l.tg/ml ozone/ml of blood but
rapidly returning to baseline values), and
intraerythrocytic reduced glutathione levels (never
below 10% and rapidly restored).5 Unexpectedly and
contrary to the ozone dosage usually used in
autohaemotherapy (from 5 to 40 g/ml O per ml of
blood), we have found that we could raise the ozone
levels, and the most effective concentrations without
toxicity range between 50 and 80 l.tg/ml depending
upon the individual plasma levels of anti-oxidant
Spleen
// ,J Bone marrow
Lymphnocles/
FIG. 1. The scheme suggests that blood mononuclear cells, after
reinfusion, leave the blood compartment, home in various lymphoid and
non-lymphoid organs and release cytokines finally responsible for
the activation of the immune system. Activated erythrocytes improve
oxygenation and metabolism.
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compounds. The concept46,49 of correlating the pro-
duction of cytokines by blood mononuclear cells vs.
ozone concentration has represented a crucial advan-
tage and it has become an indispensable end-point.
Today it has become unthinkable to assess the cor-
rectness of the ozone concentrations by bubbling the
gas through the blood sample, as has been done
recently. 56
On the other hand it appears evident that the
exposure of a precise volume of blood to a known
volume of ozone with a predetermined concentra-
tion and for a definite time allows a reliable
stoichiometric procedure. For each auto-
haemotherapeutic treatment we advise collecting
250-300 ml of blood in bags containing 25 IU/ml of
calciheparin/ml of blood plus 5 mM Ca"*. The elimi-
nation of the commonly used anticoagulant solution
of citrate-phosphate-dextrose (CPD) and the addi-
tion of 5 mM Ca"* markedly enhances the production
of cytokines as reported in detail elsewhere. 49,51 This
point is emphasized because in viral infections it is
necessary to activate the cellular immune response
with the aim of eradicating or at least slowing the
progress of the disease.
The ozone generator is reliable and ozone concen-
tration can be precisely checked by photometric
analysis. The OJO gas mixture is simply and rapidly
added with a syringe to reach a final concentration
of 70 l.tg/ml ozone per ml of blood. A modest
hyperbaric pressure occurs as commercially available
bags of 450 ml may finally contain 300 ml of blood
and 240 ml of gas mixture. In terms of cytokine
induction, an ozone concentration below 40 l.tg/ml is
modestly effective and our recent experience has
taught us that, depending upon the variable presence
of antioxidants in the plasma, a range of ozone
concentration between 50 and 80 I.tg/ml gives reli-
able results and currently we use 70 t.tg/ml/per ml of
blood.
Immediately after the gas addition, the bag is
gently mixed up and down by hand for up to 5 min.
After carrying out analysis of the pO,., pCO2 and pH
every minute, we have noted that within 3-5 minutes
the pO2 tension reaches a plateau. The fact that
ozone is more soluble than oxygen suggests no
further need of mixing and transfusion in the donor
is carried out during the following 20-30 min with
occasional mixing to minimize erythrocyte sedimen-
tation. The speed of reinfusion is checked by a
common set for blood transfusion. The procedure is
therefore simple, without needing any technical de-
vice so that it could be easily carried out even in
poorly equipped hospitals in third-world countries.
The frequency of treatments is fairly flexible but
the preferred schedule is thrice weekly for the first
two months and twice weekly for the following four
months. Even if a total blood volume of about 17
is exposed to ozone during this period, it corre-
sponds to only about 7% of the lymphocyte mass.4,57
If it is beneficial, the treatment can be continued
once a week, or every other week, indefinitely.
Autohaemotherapy does not procure side effects
and often patients report a sense of well-being and
euphoria. In comparison to the toxic syndrome
noted after administration of potent cytokine induc-
ers, 58,s9 reasons for the lack of toxicity after
autohaemotherapy discussed at length elsewhere4
can be attributed to the physiological-like release of
cytokines in various cellular microenvironments
after the homing of the reinfused cells. The scheme
reported in Fig. 1 illustrates how activated immune
cells may circulate without any substantial increase
of cytokine lev.els in the circulation which is the main
cause of toxicity after pharmacological administra-
tion.3,-.
Conceptual and technical disadvantages
of this approach
First, although the activation ex vivo of blood
mononuclear cells with ozone is very mild, the pos-
sibility cannot be excluded that some cytokines such
as TNFot and GM-CSF may reactivate the replication
of a latent HIV infection.61,6 Furthermore, particularly
in the first phase of the treatment, increased
oxidative stress in HIV positive subjects and the
killing of infected cells may also favour the reactiva-
tion of the disease. This possibility is clearly serious
and must be controlled (at least in the initial phase)
by a concomitant administration of zidovudine, N-
acetyl-t-cysteine and by strictly monitoring cellular,
immunological and virological markers as well as the
clinical status for eventually interrupting the treat-
ment. In order to stabilize the plasma levels of anti-
oxidants and to make sure that patients receive a
normal vitaminic support we have always prescribed
a daily multivitamin (including vitamin C and E)
supplement.
Subjects hypersensitive to heparin or under anti-
coagulant therapy, or aspirin, or prone to the
haemorrhagic syndrome, or thrombocytopenia have
to be carefully evaluated before inclusion. Other
criteria for exclusion do not need to be discussed
here. If venous access is very difficult, alternative
possibilities are discussed in the following section.
Are other routes of administration of
ozone equally useful?
MattassP has extensively reviewed this issue and
one is amazed by the number of administration
routes (Table 2) and the relatively low toxicity most
likely inhibited by the body anti-oxidant reservoir.45
Unfortunately, therapeutic efficacy has been evalu-
ated in most cases in anecdotic fashion and for these
various routes it appears impossible to define a
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Table 2. Routes for the administration of ozone
Parenteral Local insufflation
Intravenous Nasal
Intra-arterial Tubal
Intramuscular Oral
Subcutaneous Vaginal
ntra-articular Vesical
Rectal
Cutaneous
stoichiometric relationship as there is between a
precise volume of blood and ozone. In fact, even by
controlling the volume of gas infused, the volume of
blood flowing in a vessel or being exposed in an
internal cavity or tissue, remains unknown. Thus, the
first drawback is that ozone dosage has to be defined
on a trial and error basis.
In spite of a slow and controlled administration,
and of 0,/0 solubility and capillary absorption, the
intra-arterial and particularly intravenous routes can
be painful and predispose to pulmonary embolism.
When up to a total of 120ml of gas have been
intravenously injected daily, ozone may give rise to
a transient toxic syndrome. Administration of a fairly
large volume of ozone (up to 100 ml) via intramus-
cular and subcutaneous routes is usually painful
and therapeutic efficacy remains unclear. Since last
year, as an alternative to these routes and
autohaemotherapy, we have been evaluating the
infusion of isotonic saline (300 ml) contained in a 500
ml glass bottle saturated with 360 ml of 02/0 (38 mg
of ozone). Even patients with precarious venous
access show a good compliance and so far, no
untoward effects have been noted.
Fahmy3 has .reported that intra-articular adminis-
tration of ozone associated or not to auto-
haemotherapy can be beneficial in rheumatoid
arthritis. This is surprising because at the site of the
rheumatoid lesion there is an abnormal release of
inflammatory cytokines and active radicals, and one
would expect that injection of ozone would worsen
the disease. Thus, the paradoxic effect of ozone
could be tentatively explained by either the en-
hanced release of cytokine antagonists or of
cytokines such as IL-10 and TGFI able to suppress
autoreactive cytotoxic T cells, or by ablating the
production of autoantigens, or by inducing the ex-
pression of superoxide dismutase.
Of the various local treatments, the cutaneous one
(for torpid ulcers or necrotic lesions due to chronic
limb ischaemia), when properly done, is free of side
effects and effective especially when combined to
autohaemotherapy.64
Rectal insufflation of up to 800 ml of 02/0 has
been practised with beneficial effects in AIDS pa-
tients with intractable diarrhoea.65 The same route
was evaluated by Knoch et al. showing significant
metabolic modifications as measured by haemogas
(higher pO than normal) and biochemical analysis.
These results imply conspicuous absorption of 02/0
through the mucosal lining with consequent effects
on intestinal capillary blood. Usually, insufflation of
about 300 ml of 02/0 with an ozone concentration
of 20 ILtg/ml (i.e. a total of 6 mg of ozone), 2-3 times
weekly, is well tolerated and seems effective in the
treatment of chronic hepatitis and may be useful in
HIV infected patients without venous access. How-
ever,, in comparison to haemotherapy, unless we
define some markers, it appears difficult to establish
an optimal dosage for this route. Nonetheless, it
would be worthwhile to clarify whether there is
some ozone absorption via intestinal lymphatics with
the possibility of either activating mononuclear cells
in intestinal lymph and in the vast retroperitoneal
lymph node network. Ozone may subtly alter
mucosal permeability thus enhancing absorption via
lymphatics of compounds derived from the bacterial
flora with immunoenhancing properties. With regard
to this, insufflation of 02/0 in the peritoneal cavity
may also offer some advantages although this route
is not as practical as the rectal one.
Concluding remarks
HIV infection poses a challenging medical problem
with no ready solution in sight. However, the obser-
vation that a few patients can survive in an appar-
ently healthy state for over 10 years after HIV infec-
tion has provided an important clue for tackling the
problem. As a matter of fact it is well known that,
during epidemics, a variable percentage of humans
can resist and even overcome the most virulent viral
infection, depending upon the efficiency of their
immune system. This certainly depends upon a
number of genetic, metabolic, hormonal and nutri-
tional factors but there are no fool-proof markers to
Leukocyte activation
Improved oxygenation
Virucidal effect
Neuroendocrine
factors?
CD4 mH
CD8
GO4+ 3"
Short-term survivors
FIG. 2. The scheme indicates the dynamic situation that may lead either to
AIDS or to an apparent disease-free state. The balance may tilt towards
long survival by using autohaemotherapy after exposing autologous blood
to OJOa.
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predict the individual resistance to the infection. A
limitation of the proposed approach is to select HIV
infected people that are likely to benefit from the
therapy and this will impose strict eligibility criteria.
With regard to selection of potentially responsive
patients, a meaningful approach based on the evalu-
ation of TH function has been proposed by
CleriCi and Shearer5,13 and may be useful. As shown
in Fig. 2, the aim is to modify the natural course
of the disease by activating cellular immune
reactivity, thus creating the condition for a longer
survival.
An obvious and pressing question is what to do
when patients have progressed to AIDS. While the
approach proposed here may well be useless or even
detrimental because it may upregulate HIV replica-
tion, one has to be extremely cautious in attempting
allohaemotherapy because ozone-activated, allo-
genic lymphocytes may cause graft vs. host diseasel
At present, therapy with biological response modi-
fiers has not been rewarding but nonetheless several
approaches are being evaluated.67,68 In spite of sev-
eral observations69-72 of suppression of HIV replica-
tion in blood mononuclear cells in vitro, IFNcz and [3,
used as single agents, are minimally useful in HIV
infected patients,3 except in Kaposi’s sarcoma. 28,29
Administration of polyethylene/glycol modified IL-2
may improve CD4 cell counts31 but it procures a
certain level of toxicity and may perturb the cytokine
network with an unpredictable outcome. Gene
therapy, after cloning the IL-2 and IFN7 genes in
lymphocytes, offers the alternative possibility of an
endogenous, physiological-like process but, besides
the technical problem and the cost of a personalized
therapy, there remains the problem of getting an
optimal and stable therapeutic level. Administration
of haematopoietic growth factors may be useful but
it needs to be optimized and made safe regarding
modulation of HIV replication.73
Thus the procedure of autohaemotherapy appears
advantageous because it is simple to perform and
potentially effective because it involves an equili-
brated release of type l-like cytokines. In compari-
son to potent mitogens, ozone induces a small pro-
duction of cytokines that, owing to a physiological
distribution, does not procure toxicity Although it
cannot be measured, ozone may also induce .the
production of CAF or other factors involved in block-
ing HIV infection. Moreover the procedure is safe
and so inexpensive to be afforded by third-world
countries.
Autohaemotherapy was first introduced by
Wehrly34 in 1954 but unfortunately it has been used
in an empirical fashion and without knowing the
relevant mechanism of action. By mere coincidence,
stumbled upon this problem and hope to have
contributed ’to teach an old method new tricks’ that
may be exploited for restoring human health.
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